Repurposed Anti-Nausea Drug TEP Tested for Clearing Alzheimer's Brain Plaques
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
Summary
Researchers ran a Phase 2 proof-of-mechanism trial testing thiethylperazine (TEP), a drug approved since 1961 for nausea and vertigo, as a potential treatment for early Alzheimer's disease. The premise is intriguing: preclinical studies in AD mouse models showed TEP actively promotes the transport of toxic amyloid beta peptides out of the brain and into the bloodstream, and also improved learning deficits in animals. Because TEP has decades of safety data behind it, it offered a fast-track candidate for human testing. The trial enrolled 20 participants with early-to-mild Alzheimer's and compared them to healthy volunteers. Investigators measured whether TEP raised blood levels of amyloid beta — a proxy for enhanced brain clearance — and tracked cognitive outcomes. The trial was completed in October 2021, though full results have not been published in peer-reviewed literature yet.
Detailed Summary
Alzheimer's disease remains one of the most devastating and treatment-resistant conditions facing aging populations. One emerging hypothesis focuses not on preventing amyloid beta production but on accelerating its removal from the brain. This trial tested whether a repurposed drug could do exactly that.
Thiethylperazine (TEP) is a phenothiazine-class medication approved since 1961 primarily for nausea, vomiting, and vertigo. Its established safety profile made it an appealing candidate for rapid clinical translation. Preclinical work in Alzheimer's mouse models demonstrated that TEP promotes active transport of amyloid beta peptides across the blood-brain barrier into peripheral blood — effectively draining the brain of toxic protein aggregates. The same animal studies also reported improvements in learning and memory deficits.
This multicenter Phase 2 proof-of-mechanism trial enrolled 20 subjects with early-to-mild Alzheimer's disease and compared their response to healthy volunteers. The primary question was whether TEP could measurably increase blood amyloid beta levels in AD patients — a biomarker signal indicating enhanced brain-to-blood transport. Secondary outcomes included assessments of cognitive function. The trial ran from late 2017 through October 2021.
The results of this completed trial have not yet appeared in full peer-reviewed publication, limiting interpretation. If TEP successfully elevated peripheral amyloid beta in AD patients compared to controls, it would validate the transport mechanism in humans and support progression to larger efficacy trials. Even a modest signal would be scientifically significant given the drug's known safety record and low development cost as a repurposed agent.
Caveats are substantial: the sample size of 20 is very small, restricting statistical power. The trial design is proof-of-mechanism rather than efficacy-focused, meaning cognitive improvement was not the primary endpoint. Full peer-reviewed results are pending, and the long gap since completion raises questions about outcome reporting.
Key Findings
- TEP, a 60-year-old antiemetic, may enhance amyloid beta clearance from the brain into the bloodstream.
- Preclinical AD mouse models showed TEP improved learning deficits alongside amyloid drainage.
- The trial is one of few to target amyloid removal via transport enhancement rather than production inhibition.
- Small 20-person enrollment limits statistical power; full results are not yet peer-reviewed.
- TEP's long safety record could accelerate clinical translation if mechanism is confirmed in humans.
Methodology
This is a multicenter Phase 2 proof-of-mechanism trial comparing TEP treatment in 20 subjects with early-to-mild Alzheimer's disease against healthy volunteers. The primary endpoint was change in blood amyloid beta levels as a biomarker of enhanced brain-to-blood transport. The trial was sponsored by Immungenetics AG and completed in October 2021.
Study Limitations
The summary is based on the abstract and ClinicalTrials.gov registration only, as the full study results have not been published in peer-reviewed literature. The enrollment of only 20 participants severely limits statistical power and generalizability. The long gap between trial completion (October 2021) and the absence of published results introduces uncertainty about the direction and magnitude of findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.